Dublin, Oct. (GLOBE NEWSWIRE) -- "Longevity BioTech Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global longevity biotech market is experiencing rapid expansion as ...

John Dawson CBE, Deborah Ramsdell and Bruce Wendel bring corporate development, commercialization, and regulatory experience to the Company as it advances PDS0301 toward Phase 3 trial in Metastatic ...

Biopharma companies appear to be more willing to go public after a long drought. Just this week, GLP-1 developer Kailera Therapeutics and proteomics company Alamar Biosciences launched IPO roadshows ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Researchers are increasingly using AI and biotechnology tools to better understand the ...

Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The ...

WASHINGTON — A broad tariff on imported pharmaceuticals took effect at the end of September, and some biopharma companies and ...

For investors, NDA acceptance is often an important milestone because it confirms that the FDA has agreed to review the submission. Acceptance can reduce regulatory uncertainty and shift investor ...

The biotech company is downsizing to fund another trial after a drug showed no meaningful benefit. The move comes just a year after its IPO.

A surge in U.S.-China transactions is drawing scrutiny in Washington, where some lawmakers are pushing to slow the pace of investment.

A US-based biotechnology company claims it has made progress towards resurrecting the extinct dodo. Colossal Biosciences, a ...